Encapsulation of eptifibatide in RGD-modified nanoliposomes improves platelet aggregation inhibitory activity
H Bardania, SA Shojaosadati, F Kobarfard… - Journal of thrombosis …, 2017 - Springer
Eptifibatide is an antiplatelet drug used for the treatment of thrombosis. However, as a result
of its accumulation in non-targeted tissues and short half-life, it has a limited efficacy. In this …
of its accumulation in non-targeted tissues and short half-life, it has a limited efficacy. In this …
Encapsulation of eptifibatide in RGD-modified nanoliposomes improves platelet aggregation inhibitory activity
H Bardania, SA Shojaosadati, F Kobarfard… - Journal of Thrombosis …, 2016 - infona.pl
Eptifibatide is an antiplatelet drug used for the treatment of thrombosis. However, as a result
of its accumulation in non-targeted tissues and short half-life, it has a limited efficacy. In this …
of its accumulation in non-targeted tissues and short half-life, it has a limited efficacy. In this …
Encapsulation of eptifibatide in RGD-modified nanoliposomes improves platelet aggregation inhibitory activity.
H Bardania, SA Shojaosadati, F Kobarfard… - … of Thrombosis and …, 2017 - europepmc.org
Eptifibatide is an antiplatelet drug used for the treatment of thrombosis. However, as a result
of its accumulation in non-targeted tissues and short half-life, it has a limited efficacy. In this …
of its accumulation in non-targeted tissues and short half-life, it has a limited efficacy. In this …
Encapsulation of eptifibatide in RGD-modified nanoliposomes improves platelet aggregation inhibitory activity
H Bardania, SA Shojaosadati… - … of thrombosis and …, 2017 - pubmed.ncbi.nlm.nih.gov
Eptifibatide is an antiplatelet drug used for the treatment of thrombosis. However, as a result
of its accumulation in non-targeted tissues and short half-life, it has a limited efficacy. In this …
of its accumulation in non-targeted tissues and short half-life, it has a limited efficacy. In this …
Encapsulation of eptifibatide in RGD-modified nanoliposomes improves platelet aggregation inhibitory activity
H Bardania, SA Shojaosadati… - … of Thrombosis and …, 2017 - search.proquest.com
Eptifibatide is an antiplatelet drug used for the treatment of thrombosis. However, as a result
of its accumulation in non-targeted tissues and short half-life, it has a limited efficacy. In this …
of its accumulation in non-targeted tissues and short half-life, it has a limited efficacy. In this …
[PDF][PDF] Encapsulation of eptifibatide in RGD-modified nanoliposomes improves platelet aggregation inhibitory activity
H Bardania, SA Shojaosadati, F Kobarfard, F Dorkoosh… - 2016 - academia.edu
J Thromb Thrombolysis DOI 10.1007/s11239-016-1440-6 from the ex vivo study showed that
the antiplatelet activity of eptifibatide encapsulated nanoliposomes was higher in …
the antiplatelet activity of eptifibatide encapsulated nanoliposomes was higher in …
[PDF][PDF] Encapsulation of eptifibatide in RGD-modified nanoliposomes improves platelet aggregation inhibitory activity
H Bardania, SA Shojaosadati, F Kobarfard, F Dorkoosh… - 2016 - academia.edu
J Thromb Thrombolysis DOI 10.1007/s11239-016-1440-6 from the ex vivo study showed that
the antiplatelet activity of eptifibatide encapsulated nanoliposomes was higher in …
the antiplatelet activity of eptifibatide encapsulated nanoliposomes was higher in …